The burden of mental health challenges often falls heavily upon young adults. Results from the National Survey on Drug Use and Health in 2021 showed that the prevalence of major depressive disorder was the highest among individuals aged 18-25 (Substance Abuse and Mental Health Services Administration, 2022). Depression can cast shadows on what should be the brightest years. Though several treatments have emerged for depression, 30% of individuals with this disorder have shown to be treatment-resistant to many of these therapies (Zhdanava et al., 2021). Amidst this struggle, ketamine has emerged as an unexpected ray of hope. Though often associated with recreational use, ketamine’s potential as a groundbreaking treatment for depression is capturing the attention of scientists, researchers, and mental health professionals alike. This blog aims to explore the transformative effects of ketamine and its potential to offer lasting relief from depression, particularly among young adults.
Ketamine, originally developed as an anesthetic for specific medical procedures, holds a significant position on the World Health Organization Model List of Essential Medicines, indicating its vital role in medical practice (Chang et al., 2016). Although its history as an anesthetic is well-established, ketamine has emerged as a remarkable player in the world of mental health over recent years. Its unique capability to induce an altered state of consciousness is associated with profound spiritual experiences that are becoming increasingly recognized for their therapeutic potential (Sos et al., 2013).
These spiritual experiences have been reported by individuals undergoing ketamine-assisted therapy. They often involve a sense of transcendence, interconnectedness, and a profound shift in one’s perception of the world (Ko et al., 2022; Marguilho et al., 2023). Such experiences can provide a unique opportunity for personal meaningful insight, which may increase therapeutic benefit (Carhart-Harris et al., 2017). This facet of ketamine therapy offers remarkable insights into the intricate workings of the human mind and its astonishing capacity for transformation, enhancing our understanding of the brain and enabling us to apply this knowledge in innovative ways.
Neuroscience of Ketamine
Ketamine’s impact extends into the realm of neuroplasticity, which is the brain’s extraordinary ability to reorganize itself by forming new neural connections and modifying existing ones. By blocking the binding of glutamate, the brain’s primary excitatory chemical messenger, ketamine sets into motion a cascade of effects. One of these effects is the formation of new neuron-to-neuron connections, called synapses. This synaptic growth can potentially enhance memory, learning, and emotional regulation (Zunszain et al., 2013). Moreover, the effect of ketamine on the glutamate system is what underscores its potential to influence cognitive processes and mood regulation (Hillhouse & Porter, 2015).
Treatment for Depression
In controlled settings, ketamine-assisted therapy shows promise of therapeutic breakthroughs, with various studies demonstrating its sustained benefits for individuals struggling with depression (Abbar et al., 2022; Mandal et al., 2019). One study found that 63% of individuals receiving 0.5 mg/kg of ketamine infusion achieved complete elimination of suicidal thoughts compared to placebo after three days (Abbar et al., 2022). Another study found that there were significant and rapid improvements in depression symptoms in individuals receiving 0.5 mg/kg of ketamine (Mandal et al., 2019). Notably, what sets ketamine apart from conventional antidepressants is its ability to deliver significant impact within a limited exposure period, contrasting with the long-term and repetitive nature of other treatment approaches.
For young adults grappling with treatment-resistant depression, the promise of ketamine is particularly encouraging (Serafini et al., 2014). Traditional approaches to depression treatment, while effective for many, can fall short for those resistant to their effects. This is where ketamine steps in, showing a remarkable potential to provide rapid relief. Treatment-resistant depression is a common challenge in mental health care, which is why ketamine offers a promising alternative for individuals who have not responded well to conventional treatments. Clinical studies have demonstrated that ketamine infusion can induce a significant reduction in depressive symptoms, often within hours of administration (Mandal et al., 2019). The emergence of ketamine as a potential treatment offers new hope for young individuals and opens avenues for greater engagement, productivity, and enjoyment of life experiences.
Ethics & Limitations
As with any innovative treatment, ethical considerations must be incorporated into the narrative. Ketamine’s dual use for therapeutic progress and recreational misuse demands careful thought. Striking the right balance between these two facets stands as a challenge. To maintain this balance, several key steps must be taken, including stringent regulation and access control, comprehensive mental health assessments, and educating patients about risks and benefits.
One of the prominent limitations of ketamine is the lack of knowledge regarding its long-term effects. While numerous studies have explored ketamine’s efficacy as a short-term treatment for depression, the scope of research on its extended impact is limited. Furthermore, it is crucial to acknowledge that ketamine use, even in the short term, may entail immediate side effects, such as dissociation and increased heart rate, which should be closely monitored and addressed within the context of its therapeutic application (Drug Enforcement Administration, 2020). This uncertainty underscores the importance of ongoing investigations into the full spectrum of ketamine’s implications on both biological systems and behavioral patterns.
Conclusion
For young adults navigating the landscape of mental health challenges, ketamine’s evolution from a recreational substance to a potential breakthrough offers a beacon of hope. While multiple studies have illuminated the positive outcomes associated with ketamine treatment, it is important to delve deeper into the scientific exploration of this compound and its potential therapeutic benefits. This comprehensive scrutiny not only safeguards ethical considerations but also ensures that the promise of ketamine is realized in a manner that is responsible, safe, and effective.
Written by Hoda AbouEich, BS, BA and Anamar Flores, BS and edited by Stephanie Palacio, PhD and Aldrin V. Gomes, PhD.
References
Abbar, M., lLORCA, P-M., Demaricourt, P., Courtet, P., Gorwood, P.Llorca (2022). Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ. 376:e067194.
Carhart-Harris, R.L., Bolstridge, M., Day, C.M.J., Rucker, J., Watts, R., Erritzoe, D.E., Kaelen,
M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J.A., Forbes, B., Feilding, A., Taylor, D., Curran, H.V., & Nutt, D.J. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 235(2):399-408.
Chang, L. C., Rajagopalan, S., & Mathew, S. J. (2016). The history of ketamine use and its
clinical indications. Ketamine for treatment-resistant depression: The first decade of progress, 1-12.
Department of Justice, Drug Enforcement Administration. (2020). Drug fact sheet:
Hillhouse, T.M., & Porter, J.H. (20 15) A brief history of the development of antidepressant
drugs: from monoamines to glutamate. Exp. Clin. Psychopharmacol 23, 1–2.
Ko, K., Knight, G., Rucker, J.J., & Cleare, A.J. (2022) Psychedelics, Mystical Experience, and
Therapeutic Efficacy: A Systematic Review. Front. Psychiatry 13:917199.
Mandal, S., Sinha, V.K., & Goyal, N. (2019). Efficacy of ketamine therapy in the treatment of
depression. Indian J Psychiatry. 61(5):480-485.
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2023). A unified model of ketamine's
dissociative and psychedelic properties. J Psychopharmacol. 37(1):14-32.
Rucker, J.H., Iliff, J., & Nutt, D.J. (2018). Psychiatry & the psychedelic drugs. Past, present &
future. Neuropharmacology. 2018 Nov;142:200-218.
Serafini, G., Howland, R.H., Rovedi, F., Girardi, P., & Amore, M. (2014) The role of ketamine in
treatment-resistant depression: a systematic review. Curr Neuropharmacol. 444-61.
Sos, P., Klirova, M., Novak, T., Kohutova, B., Horacek, J., & Palenicek, T. (2013) Relationship
of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett. 34(4):287-93.
Substance Abuse and Mental Health Services Administration. (2022). Key substance use and
mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
Zhdanava, M., Pilon, D., Ghelerter, I., et al. (2021). The prevalence and national burden of
treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 82(2):20m13699.
Zunszain, P., Horowitz, M., Cattaneo, A., Lupi, M.M., & Pariante, C.M. (2013). Ketamine:
synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol Psychiatry18, 1236–1241.
Comments